Alnylam, awaiting key study data, builds case for its next rare disease drug

Alnylam Pharmaceuticals on Friday disclosed new results supporting the case for a new drug it's been developing for transthyretin amyloidosis, or TTR, a rare genetic disorder that's become a competitive space among drugmakers.